Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 6 | 2025 | 254 | 1.540 |
Why?
|
| Pulmonary Embolism | 4 | 2022 | 226 | 1.200 |
Why?
|
| Cardiac Tamponade | 2 | 2018 | 20 | 1.110 |
Why?
|
| Thrombosis | 6 | 2021 | 309 | 0.770 |
Why?
|
| Haemophilus influenzae | 2 | 2018 | 16 | 0.710 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 9 | 0.550 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 21 | 0.540 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 48 | 0.520 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 226 | 0.520 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 111 | 0.500 |
Why?
|
| Renal Veins | 1 | 2017 | 26 | 0.500 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 32 | 0.500 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 139 | 0.500 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 89 | 0.470 |
Why?
|
| Catheterization | 1 | 2017 | 218 | 0.460 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2022 | 180 | 0.450 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 375 | 0.420 |
Why?
|
| Anticoagulants | 3 | 2021 | 457 | 0.400 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 140 | 0.380 |
Why?
|
| Recycling | 1 | 2012 | 3 | 0.380 |
Why?
|
| Water Purification | 1 | 2012 | 4 | 0.380 |
Why?
|
| Waste Disposal, Fluid | 1 | 2012 | 3 | 0.380 |
Why?
|
| Filtration | 1 | 2012 | 27 | 0.370 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 290 | 0.370 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 257 | 0.360 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 292 | 0.360 |
Why?
|
| Ultrasonic Therapy | 2 | 2025 | 42 | 0.360 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 239 | 0.360 |
Why?
|
| Tissue Engineering | 1 | 2013 | 202 | 0.350 |
Why?
|
| Water Pollutants, Chemical | 1 | 2012 | 140 | 0.340 |
Why?
|
| Heparin | 2 | 2021 | 177 | 0.320 |
Why?
|
| Cardiac Catheterization | 5 | 2016 | 295 | 0.310 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 48 | 0.300 |
Why?
|
| Shock, Cardiogenic | 4 | 2016 | 168 | 0.300 |
Why?
|
| Heart-Assist Devices | 5 | 2016 | 882 | 0.290 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2013 | 128 | 0.250 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1260 | 0.250 |
Why?
|
| Biomarkers | 4 | 2021 | 1912 | 0.250 |
Why?
|
| Exercise Therapy | 1 | 2007 | 94 | 0.240 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 436 | 0.230 |
Why?
|
| Nitric Oxide | 1 | 2007 | 281 | 0.230 |
Why?
|
| Femoral Vein | 1 | 2025 | 42 | 0.220 |
Why?
|
| Stem Cells | 1 | 2007 | 386 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 217 | 0.210 |
Why?
|
| Humans | 28 | 2022 | 93607 | 0.210 |
Why?
|
| Aortic Valve | 2 | 2017 | 250 | 0.190 |
Why?
|
| Phantoms, Imaging | 3 | 2021 | 484 | 0.190 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 332 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2022 | 36 | 0.180 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2016 | 263 | 0.170 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 49 | 0.170 |
Why?
|
| Embolectomy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Antithrombins | 1 | 2020 | 19 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 98 | 0.160 |
Why?
|
| Middle Aged | 16 | 2021 | 27620 | 0.160 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 51 | 0.160 |
Why?
|
| Female | 16 | 2021 | 48771 | 0.150 |
Why?
|
| Europe | 1 | 2020 | 337 | 0.150 |
Why?
|
| Elastic Modulus | 1 | 2019 | 34 | 0.150 |
Why?
|
| Gels | 1 | 2019 | 51 | 0.150 |
Why?
|
| Lithotripsy | 1 | 2019 | 43 | 0.150 |
Why?
|
| Aged | 12 | 2021 | 20469 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 235 | 0.150 |
Why?
|
| Cardiology | 1 | 2020 | 120 | 0.150 |
Why?
|
| Microbubbles | 1 | 2019 | 39 | 0.150 |
Why?
|
| Recurrence | 2 | 2020 | 1191 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2021 | 702 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2022 | 9108 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 657 | 0.140 |
Why?
|
| Acute Disease | 1 | 2020 | 841 | 0.140 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Pericarditis | 1 | 2018 | 14 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2019 | 116 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 215 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 15 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 168 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 295 | 0.130 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 103 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 75 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2020 | 2444 | 0.130 |
Why?
|
| Phlebography | 1 | 2017 | 68 | 0.130 |
Why?
|
| Male | 16 | 2021 | 44578 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 623 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 72 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1715 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1531 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 247 | 0.120 |
Why?
|
| Heart Failure | 3 | 2016 | 1388 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 610 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 147 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 225 | 0.100 |
Why?
|
| Pericytes | 1 | 2013 | 14 | 0.100 |
Why?
|
| Adult | 8 | 2022 | 27953 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2016 | 257 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 254 | 0.100 |
Why?
|
| Software | 1 | 2017 | 670 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 629 | 0.090 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 4 | 0.090 |
Why?
|
| Water Movements | 1 | 2012 | 9 | 0.090 |
Why?
|
| London | 1 | 2012 | 15 | 0.090 |
Why?
|
| Water Pollution | 1 | 2012 | 10 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2013 | 66 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 216 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2592 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 392 | 0.090 |
Why?
|
| Metals, Heavy | 1 | 2012 | 17 | 0.090 |
Why?
|
| RNA Interference | 1 | 2013 | 379 | 0.090 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 28 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 128 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2013 | 477 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 836 | 0.090 |
Why?
|
| Water Supply | 1 | 2012 | 66 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2016 | 311 | 0.090 |
Why?
|
| Catheters | 2 | 2022 | 96 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 184 | 0.090 |
Why?
|
| Swine | 2 | 2025 | 587 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 804 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 657 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2021 | 289 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 520 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 947 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2013 | 714 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2021 | 483 | 0.070 |
Why?
|
| Septal Occluder Device | 3 | 2013 | 49 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1516 | 0.070 |
Why?
|
| Nitrites | 1 | 2007 | 34 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 2543 | 0.060 |
Why?
|
| Exercise Test | 1 | 2007 | 152 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 246 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1525 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 238 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 113 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 712 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 884 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2025 | 36 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 52 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2025 | 129 | 0.050 |
Why?
|
| Critical Illness | 2 | 2021 | 343 | 0.050 |
Why?
|
| Animals | 4 | 2025 | 28041 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3835 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 494 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 158 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 982 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 217 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 223 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 394 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3498 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 319 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 73 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2019 | 476 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7073 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 32 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 135 | 0.040 |
Why?
|
| Mice | 2 | 2013 | 12233 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2013 | 297 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 654 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2022 | 150 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2022 | 191 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 239 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 10186 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 293 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 242 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 713 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 46 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 412 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 157 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 423 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1246 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2491 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 775 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 5405 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1723 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 118 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 54 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 273 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 828 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 248 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 92 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 505 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 996 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1262 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 49 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1923 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 117 | 0.020 |
Why?
|
| United States | 2 | 2016 | 7645 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2718 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 920 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 703 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1954 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1464 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1918 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 39 | 0.010 |
Why?
|
| Filgrastim | 1 | 2004 | 56 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 78 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 49 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 5911 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 161 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 320 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2828 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1610 | 0.010 |
Why?
|